Citations

Clear

3942 citation(s) found for "To, Van".

A Phase 1b Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Stem Cell Transplantation
Tejura, Bindu, Ford, Christopher B. , Lombardo, Mary Jane, Kosuri, Satyajit, Khera, Nandita , DeFilipp, Zachariah , Moltke, Lisa Von, Ponce, Doris M , Peled, Jonathan U. , Tejura, Bindu, van den Brink, Marcel R M , Lombardo, Mary‐Jane

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10532-10533

10.1182/blood-2022-162386 Get It

Relevance of Monitoring Thymic Function and Recovery in Interpreting Immune Reconstitution Post Hematopoietic Cell Transplantation in Inborn Errors of Immunity
Hee, Michelle Van, Dong, Xiangyang , Knight‐Perry, Jessica, Abraham, Roshini S. , Drozdov, Daniel , Bunch, Dustin R. , Luo, Xianghua , Ebens, Christen L.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4778-4779

10.1182/blood-2022-158373 Get It

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
Oluwole, Olalekan O. , Forcade, Édouard , Muñoz, Javier, Guibert, Sophie de , Lin, Yi , Deol, Abhinav , McSweeney, Peter A., Kersten, Marie José , Jacobson, Caron A. , Thiéblemont, Catherine , Timmerman, John M. , Stiff, Patrick J. , Tzachanis, Dimitrios , Zheng, Yan , Vardhanabhuti, Saran , Shen, Rhine R. , Miao, Harry , Kim, Jenny , Oluwole, Olalekan O , Vose, Julie M. , Bartlett, Nancy L. , Goy, Andre Henri , Farooq, Umar , Minnema, Monique C , Avivi, Irit , Nater, Jenny , Meerten, Tom van

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10399-10401

10.1182/blood-2022-156117 Get It

Novel Genetic Determinants of Dental Maturation in Children
Grgić, Olja, Prijatelj, Vid , Dudakovic, Amel , Vucic, S. , Dhamo, Brunilda , Monnereau, Claire , Zrimšek, Maša , Gautvik, Kaare M. , Reppe, Sjur , Shimizu, Emi , Haworth, Simon , Timpson, Nicholas J. , Uitterlinden, André G. , Ongkosuwito, Edwin M. , Wijnen, André J. van , Rivadeneira, Fernando , Wolvius, Eppo B. , Prijatelj, V , Vucic, S , Dhamo, B , Zrimsek, M , Haworth, S , van Wijnen, Andre J , Trajanoska, Katerina , Jaddoe, Vincent W. V. , Järvelin, Marjo‐Riitta , Evans, David M. , Medina‐Gómez, Carolina

Mayo Clinic

Journal of Dental Research | November 28, 2022 | Volume: 102 | Issue: 3 | Pages: 349-356

10.1177/00220345221132268 | PMID 36437532 Get It

Dental occlusion requires harmonious development of teeth, jaws, and other elements of the craniofacial complex, which are regulated by environmental and genetic factors. We performed the first genome-wide association study (GWAS) on dental development (DD) using the Demirjian radiographic method. Radiographic assessments from participants of the Generation R Study (primary study population, N 1 = 2,793; mean age of 9.8 y) were correlated with ~30 million genetic variants while adjusting for age, sex, and genomic principal components (proxy for population stratification). Variants associated with DD at genome-wide significant level ( P < 5 × 10 −8 ) mapped to 16q12.2 ( IRX5) (lead variant rs3922616, B = 0.16; P = 2.2 × 10 −8 ). We used Fisher’s combined probability tests weighted by sample size to perform a meta-analysis ( N = 14,805) combining radiographic DD at a mean age of 9.8 y from Generation R with data from a previous GWAS ( N 2 = 12,012) on number of teeth (NT) in infants used as proxy of DD at a mean age of 9.8 y (including the ALSPAC and NFBC1966). This GWAS meta-analysis revealed 3 novel loci mapping to 7p15.3 ( IGF2BP3: P = 3.2 × 10 −8 ), 14q13.3 ( PAX9: P = 1.9 × 10 −8 ), and 16q12.2 ( IRX5: P = 1.2 × 10 −9 ) and validated 8 previously reported NT loci. A polygenic allele score constructed from these 11 loci was associated with radiographic DD in an independent Generation R set of children ( N = 703; B = 0.05, P = 0.004). Furthermore, profiling of the identified genes across an atlas of murine and human stem cells observed expression in the cells involved in the formation of bone and/or dental tissues (>0.3 frequency per kilobase of transcript per million mapped reads), likely reflecting functional specialization. Our findings provide biological insight into the polygenic architecture of the pediatric dental maturation process.
Body mass index and molecular subtypes of colorectal cancer
Murphy, Neil , Newton, Christina C. , Papadimitriou, Nikos , Hoffmeister, Michael , Phipps, Amanda I. , Harrison, Tabitha A. , Aglago, Elom K. , Berndt, Sonja I. , Brenner, Hermann , Cao, Yin , Chang‐Claude, Jenny , French, Amy J. , Gallinger, Steven , Georgeson, Peter , Giannakis, Marios , Gruber, Stephen B. , Harlid, Sophia , Huang, Wen‐Yi , Laskar, Ruhina Shirin , Mandic, Marko , Nowak, Johnathan A., Obón‐Santacana, Mireia , Steinfelder, Robert S. , Thibodeau, Stephen N. , Trinh, Quang M. , Tsilidis, Kostas K, Guelpen, Bethany Van , Wang, Xiaoliang , Woods, Michael O. , Zaidi, Syed Hassan Ejaz , Gunter, Marc J. , Peters, Ulrike , Song, Mingyang , Song, Mingyang , Hoffmeister, Michael , Harrison, Tabitha A , Brenner, Hermann , Cao, Yin , Chen, Xuechen , Drew, David A , Harlid, Sophia , Huang, Wen-Yi , Marchand, Loïc Le , Limburg, Paul, Sun, Wei , Ugai, Tomotaka , Van Guelpen, Bethany , Wang, Xiaoliang , Woods, Michael O , Gunter, Marc J , Murphy, Neil , Song, Mingyang , Aglago, Elom K , Obón-Santacana, Mireia , Papadimitriou, Nikos , Mandic, Marko , Trinh, Quang M , Georgeson, Peter , Newcomb, Polly A. , Buchanan, Daniel D. , Chan, Andrew T. , Cheng, Iona C. , Dimou, Niki , Drew, David A. , Farris, Alton B. , Giles, Graham G. , Hsu, Li , Jenkins, Mark A. , Marchand, Loı̈c Le , Limburg, Paul J. , Lin, Yi , Ogino, Shuji , Qu, Conghui , Sakoda, Lori C. , Schoen, Robert E. , Southey, Melissa C. , Stadler, Zsofia , Sun, Wei , Toland, Amanda Ewart , Tsilidis, Kostas K, Campbell, Peter T.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 26, 2022 | Volume: 115 | Issue: 2 | Pages: 165-173

10.1093/jnci/djac215 | PMID 36445035 Get It

Abstract Background Obesity is an established risk factor for colorectal cancer (CRC), but the evidence for the association is inconsistent across molecular subtypes of the disease. Methods We pooled data on body mass index (BMI), tumor microsatellite instability status, CpG island methylator phenotype status, BRAF and KRAS mutations, and Jass classification types for 11 872 CRC cases and 11 013 controls from 11 observational studies. We used multinomial logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI) adjusted for covariables. Results Higher BMI was associated with increased CRC risk (OR per 5 kg/m2 = 1.18, 95% CI = 1.15 to 1.22). The positive association was stronger for men than women but similar across tumor subtypes defined by individual molecular markers. In analyses by Jass type, higher BMI was associated with elevated CRC risk for types 1-4 cases but not for type 5 CRC cases (considered familial-like/Lynch syndrome microsatellite instability-H, CpG island methylator phenotype-low or negative, BRAF-wild type, KRAS-wild type, OR = 1.04, 95% CI = 0.90 to 1.20). This pattern of associations for BMI and Jass types was consistent by sex and design of contributing studies (cohort or case-control). Conclusions In contrast to previous reports with fewer study participants, we found limited evidence of heterogeneity for the association between BMI and CRC risk according to molecular subtype, suggesting that obesity influences nearly all major pathways involved in colorectal carcinogenesis. The null association observed for the Jass type 5 suggests that BMI is not a risk factor for the development of CRC for individuals with Lynch syndrome.
The role of neurofilament light in genetic frontotemporal lobar degeneration
Zetterberg, Henrik , Teunissen, Charlotte E. , Kühle, Jens , Boxer, Adam L. , Rohrer, Jonathan D. , Mitic, Laura L. , Nicholson, Alexandra M., Pearlman, Rodney , McCaughey, Stella, Tatton, Nadine , Teunissen, Charlotte E , Kuhle, Jens , Boxer, Adam , Rohrer, Jonathan D , Mitic, Laura , Pearlman, Rodney , Tatton, Nadine , Zetterberg, Henrik , Swieten, John C. van

Mayo Clinic

Brain Communications | November 26, 2022 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcac310 | PMID 36694576 Get It

Abstract Genetic frontotemporal lobar degeneration caused by autosomal dominant gene mutations provides an opportunity for targeted drug development in a highly complex and clinically heterogeneous dementia. These neurodegenerative disorders can affect adults in their middle years, progress quickly relative to other dementias, are uniformly fatal and have no approved disease-modifying treatments. Frontotemporal dementia, caused by mutations in the GRN gene which encodes the protein progranulin, is an active area of interventional drug trials that are testing multiple strategies to restore progranulin protein deficiency. These and other trials are also examining neurofilament light as a potential biomarker of disease activity and disease progression and as a therapeutic endpoint based on the assumption that cerebrospinal fluid and blood neurofilament light levels are a surrogate for neuroaxonal damage. Reports from genetic frontotemporal dementia longitudinal studies indicate that elevated concentrations of blood neurofilament light reflect disease severity and are associated with faster brain atrophy. To better inform patient stratification and treatment response in current and upcoming clinical trials, a more nuanced interpretation of neurofilament light as a biomarker of neurodegeneration is now required, one that takes into account its relationship to other pathophysiological and topographic biomarkers of disease progression from early presymptomatic to later clinically symptomatic stages.
Risk of Arthroplasty in Patients with Subchondral Insufficiency Fractures of the Knee: A Matched Study of the Implantable Shock Absorber using a Validated Predictive Model
Pareek, Ayoosh , Parkes, Chad W. , Słynarski, Konrad , Śmigıelski, Robert , Merwe, Willem van der, Walawski, Jacek , Krych, Aaron J.

Mayo Clinic

The Journal of Knee Surgery | November 24, 2022 | Volume: 37 | Issue: 01 | Pages: 073-078

10.1055/a-1984-9980 | PMID 36417980 Get It

AbstractSubchondral insufficiency fractures of the knee (SIFK) can result in high rates of osteoarthritis and arthroplasty. The implantable shock absorber (ISA) implant is a titanium and polycarbonate urethane device which reduces the load on the medial compartment of the knee by acting as an extra-articular load absorber while preserving the joint itself. The purpose of this study was to evaluate whether partially unloading the knee with the ISA altered the likelihood of progression to arthroplasty utilizing a validated predictive risk model (SIFK score). A retrospective case-control (2:1) study was performed on patients with SIFK without any previous surgery and on those implanted with the ISA with the primary outcome being progression to arthroplasty compared with nonoperative treatment at 2 years. Baseline and final radiographs, as well as magnetic resonance imagings, were reviewed for the evaluation of meniscus or ligament injuries, insufficiency fractures, and subchondral edema. Patients from a prospective study were matched using the exact SIFK Score, a validated predictive score for progression to arthroplasty in patients with SIFK, to those who received the ISA implant. Kaplan–Meier analysis was conducted to assess survival. A total of 57 patients (38 controls:19 ISA) with a mean age of 60.6 years and 54% female were included. The SIFK score was matched exactly between cases and controls for all patients. The 2-year survival rate of 100% for the ISA group was significantly higher than the corresponding rate of 61% for the control group (p < 0.01). In ISA, 0% of the patients converted to arthroplasty at 2 years, and 5% (one patient) had hardware removal at 1 year. When stratified by risk, the ISA group did not have a significantly higher survival compared with low-risk (p = 0.3) or medium-risk (p = 0.2) controls, though it had a significantly higher survival for high-risk groups at 2 years (100 vs. 15%, p < 0.01). SIFK of the medial knee can lead to significant functional limitation and high rates of conversion to arthroplasty. Implants such as the ISA have the potential to alter the progression to arthroplasty in these patients, especially those at high risk.
Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials
Islam, Mahnoor, Ikram, Waleed, Naqvi, Syed Arsalan Ahmed , Riaz, Anum, Ravi, Praful , Odedina, Folakemi T., Duma, Narjust , Kehl, Kenneth L. , Kamran, Sophia C. , Bryce, Alan H. , Singh, Parminder , Riaz, Irbaz Bin , Murad, Mohammad Hassan, Bryce, Alan Haruo, Bryce, Alan H , Singh, Parminder , Maqsood, Hamza , Saleem, Yusra, Wang, Zhen , Hussain, Syed A. , Warner, Jeremy L. , Singh, Parminder Pal , Murad, M. Hassan , Landman, Adam , Van Allen, Eliezer M

Mayo Clinic

JAMA Oncology | November 23, 2022 | Volume: 9 | Issue: 2 | Pages: 180

10.1001/jamaoncol.2022.5511 | PMID 36416812 Get It

ImportanceProstate cancer (PCa) is marked by disparities in clinical outcomes by race, ethnicity, and age. Equitable enrollment in clinical trials is fundamental to promoting health equity.ObjectiveTo evaluate disparities in the inclusion of racial and ethnic minority groups and older adults across PCa clinical trials.Data SourcesMEDLINE, Embase, and ClinicalTrials.gov were searched to identify primary trial reports from each database's inception through February 2021. Global incidence in age subgroups and US population-based incidence in racial and ethnic subgroups were acquired from the Global Burden of Disease and Surveillance, Epidemiology, and End Results 21 incidence databases respectively.Study SelectionAll phase 2/3 randomized PCa clinical trials were eligible for age disparity analyses. Trials recruiting exclusively from the US were eligible for primary racial and ethnic disparity analyses.Data Extraction and SynthesisThis study was reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines. Data were pooled using a random-effects model.Main Outcomes and MeasuresEnrollment incidence ratios (EIRs), trial proportions (TPs) of participants 65 years or older or members of a racial and ethnic subgroup divided by global incidence in the corresponding age group, or US population–based incidence in the corresponding racial and ethnic subgroup, were calculated. Meta-regression was used to explore associations between trial characteristics and EIRs and trends in EIRs during the past 3 decades.ResultsOf 9552 participants among trials reporting race, 954 (10.8%) were African American/Black, 80 (1.5%) were Asian/Pacific Islander, and 8518 (78.5) were White. Of 65 US trials, 45 (69.2%) reported race and only 9 (13.8%) reported data on all 5 US racial categories. Of 286 global trials, 75 (26.2%) reported the enrollment proportion of older adults. Outcomes by race and age were reported in 2 (3.1%) and 41 (15.0%) trials, respectively. Black (EIR, 0.70; 95% CI, 0.59-0.83) and Hispanic (EIR, 0.70; 95% CI, 0.59-0.83) patients were significantly underrepresented in US trials. There was no disparity in older adult representation (TP, 21 143 [71.1%]; EIR, 1.00; 95% CI, 0.95-1.05). The representation of Black patients was lower in larger trials (meta-regression coefficient, −0.06; 95% CI, −0.10 to −0.02; P = .002).Conclusions and RelevanceThe results of this meta-analysis suggest that Black and Hispanic men are underrepresented in trials compared with their share of PCa incidence. The representation of Black patients has consistently remained low during the past 2 decades.
Deep Generative Networks for Algorithm Development in Implantable Neural Technology
Sladky, Vladimir , Balzekas, Irena , Pridalova, Tereza, Miller, Kai J. , Brinkmann, Benjamin H. , Brinkmann, Benjamin H , Mívalt, Filip , Gompel, Jamie J. Van , Denison, Timothy , Křemen, Václav , Worrell, Gregory A.

Mayo Clinic

2022 IEEE International Conference on Systems, Man, and Cybernetics (SMC) | November 18, 2022 | Volume: No volume available | Issue: No issue available | Pages: 1736-1741

10.1109/smc53654.2022.9945379 Get It